SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-001247
Filing Date
2023-01-12
Accepted
2023-01-12 09:00:23
Documents
16
Period of Report
2023-01-11
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38298
2 ex99-1.htm EX-99.1 34551
3 ex99-2.htm EX-99.2 1547
4 ex99-1_001.jpg GRAPHIC 5747
5 ex99-2_001.jpg GRAPHIC 222385
  Complete submission text file 0001493152-23-001247.txt   567888

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rspi-20230111.xsd EX-101.SCH 3230
7 XBRL LABEL FILE rspi-20230111_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE rspi-20230111_pre.xml EX-101.PRE 22361
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3292
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 23525039
SIC: 2834 Pharmaceutical Preparations